Search clinical trials for: Vaccin GenHevac B Pasteur

Total 493037 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland

Rabies (Healthy Volunteers)

Thailand
Walvax Biotechnology Co., Ltd.

Completed

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Neisseria Meningitides Meningitis

Mali
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults (COVIBOOSTAnci1)

COVID-19 Vaccines

France
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine (CoviBOOST 2)

COVID-19 | Vaccine Reaction

France
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA (VYF02)

Yellow Fever (Healthy Volunteers)

United States
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Completed

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

COVID-19 (Healthy Volunteers)

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company; Bioster, a.s.

Completed

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 (COVIMMUNAGE)

Covid19

France
Tor Biering-Sørensen
Sanofi Pasteur, a Sanofi Company; Statens Serum Institut

Completed

Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake (NUDGE-FLU)

Influenza | Behavior and Behavior Mechanisms

Denmark
Novartis Vaccines

Completed

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia

Meningococcal Disease

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States

Pertussis (Whooping Cough)

France
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
Insight Therapeutics, LLC
Brown University; Sanofi Pasteur, a Sanofi Company; Case Western Reserve University

Active, not recruiting

Recombinant Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza, Human | Influenza -Like Illness

United States
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (HVTN 120)

HIV Infections

United States, Zimbabwe, Tanzania, Zambia
Institut Pasteur
Institut Pasteur de Madagascar; Institut Pasteur du Cambodge

Completed

Immunity Persistence After Abridged Intradermal Rabies PEP (RESIST-3)

Rabies

Cambodia, Madagascar
Kaiser Permanente
Sanofi Pasteur, a Sanofi Company

Completed

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Stroke | Pneumonia | Influenza | Congestive Heart Failure | Acute Myocardial Infarction | Lower Respiratory Tract Infection

United States
Pfizer

Completed

Clostridium Difficile Vaccine Efficacy Trial (Clover)

Clostridium Difficile Infection

United States, Spain, Belgium, Taiwan, Japan, Portugal, Colombia, Korea, Republic of, Poland, Australia, Germany, Canada, Argentina, Bulgaria, Chile, Czechia, Finland, France, Hungary, Peru, Slovakia, Sweden, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Human Immunodeficiency Virus | Dengue Fever | Dengue Hemorrhagic Fever

Brazil
Institut Pasteur de Tunis

Completed

Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines

COVID-19

Tunisia
Johns Hopkins Bloomberg School of Public Health
Columbia University; Sanofi Pasteur, a Sanofi Company; Institute of Epidemiology... and other collaborators

Completed

Pregnancy, Arsenic and Immune Response (PAIR)

Influenza | Vaccine Response Impaired | Micronutrient Deficiency | Arsenic--Toxicology | Immunologic Disorders Complicating Pregnancy

Bangladesh
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Mexico
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

COVID-19

United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
University Hospital, Ghent
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; Novartis Vaccines; University... and other collaborators

Completed

Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses

Prevention of Infections With Bordetella Pertussis

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

Influenza | Flu

China
Institut Pasteur
Centre Hospitalier Territorial de Nouvelle-Calédonie; Centre Hospitalier Spécialisé... and other collaborators

Completed

Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population (COVCAL)

SARS-CoV-2 Acute Respiratory Disease

New Caledonia
Sanofi Pasteur, a Sanofi Company
Immune Design

Terminated

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (HSV15)

Genital Herpes

United States
Assistance Publique - Hôpitaux de Paris
Recherche Clinique Paris Descartes Necker Cochin Sainte Anne; EUCLID Clinical... and other collaborators

Active, not recruiting

Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. (SPLENEVAC-2)

Splenectomised Patients

France
Murdoch Childrens Research Institute
National Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaborators

Completed

Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam

Pneumococcal Vaccines

Vietnam
Tor Biering-Sørensen
Sanofi Pasteur, a Sanofi Company

Completed

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting (DANFLU-1)

Influenza

Denmark
Centre Hospitalier Annecy Genevois
Hospices Civils de Lyon; Institut National de la Santé Et de la Recherche Médicale... and other collaborators

Completed

Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression (INFLUOMICS)

Vaccine Reaction

France
Biomedical Research Center EPLS
University of Cape Town; Biofabri, S.L; TuBerculosis Vaccine Initiative; Universidad... and other collaborators

Completed

Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal (MTBVAC-EPI)

Tuberculosis

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Rabies (Healthy Volunteers)

France
Assistance Publique - Hôpitaux de Paris
COVIREIVAC

Active, not recruiting

Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination (COVIBOOST)

COVID-19 | Vaccine Reaction

France
Assistance Publique - Hôpitaux de Paris
Recherche Clinique Paris Descartes Necker Cochin Sainte Anne; EUCLID Clinical... and other collaborators

Completed

Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PNEUMOVAS)

Invasive Pneumococcal Infection

France
St. Petersburg Research Institute of Vaccines and...

Completed

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Vaccines | Haemophilus Influenzae Infection

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring (VAP00007)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
Sanofi Pasteur, a Sanofi Company

Suspended

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (QHD00014)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Polio Immunisation | Haemophilus Influenzae Type B Immunisation | Rotavirus Immunisation

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

Pertussis | Whooping Cough | Tetanus | Diphtheria

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

Pertussis

United States
Sanofi

Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

Influenza | Flu

China
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year (VAJ00001)

Healthy Volunteers (Rabies Immunization)

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam (GQM10)

Influenza

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Influenza

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Pertussis | Tetanus | Diphtheria | Bacterial Meningitis | Poliomyelitis

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Russian Federation

Search clinical trials for: Vaccin GenHevac B Pasteur

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations